Angiotensin II inhibition and prevention of atrial fibrillation and stroke

Journal of the American College of Cardiology

Volumn 45, Issue 5, 2005, Pages 720-721

  Bourassa, Martial G ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN; TRANDOLAPRIL;

CLINICAL TRIAL; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE;

EID: 14044269997     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2004.12.008     Document Type: Editorial

References (16)

1. American Heart Association Heart and Stroke Statistical Update 2003 American Heart Association Dallas, TX 1-52
2. A.S. Go, E.M. Hylek, K.A. Phillips Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulant and Risk Factors in Atrial Fibrillation (ATRIA) study JAMA 285 2001 2370 2375
3. O.D. Pederson, H. Bagger, L. Kober, C. Torp-Pederson Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 1999 376 380
4. E. Vermes, J.C. Tardif, M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 2003 2926 2931
5. K.C. Ueng, T.P. Tsai, W.C. Yu Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation Results of a prospective and controlled study Eur Heart J 24 2003 2090 2098
6. A.H. Madrid, M.G. Bueno, J.M.G. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation Circulation 106 2002 331 336
7. Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-11.
8. Wachtell K, Letho M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9.
9. Y. Shi, A. Ducharme, D. Li Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation Cardiovasc Res 52 2001 217 225
10. A. Goette, M. Arndt, C. Rocken Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans Circulation 101 2000 2678 2681
11. F. Gensini, L. Padeletti, G. Fatini, E. Sticchi, G.F. Gensini, A. Michelucci Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation Pacing Clin Electrophysiol 26 2003 295 298
12. C.T. Tsai, L.P. Lai, J.L. Lin Renin-angiotensin system gene polymorphisms and atrial fibrillation Circulation 109 2004 1640 1646
13. D. Li, K. Shinagawa, L. Pang Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardia-induced congestive heart failure Circulation 104 2001 2608 2614
14. K. Kumagai, H. Nakashima, H. Urata Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation J Am Coll Cardiol 41 2003 2197 2204
15. D. Mozaffarian, B.M. Psaty, E.B. Rimm Fish intake and risk of incident atrial fibrillation Circulation 110 2004 368 373
16. J. Dernellis, M. Panaretou Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation Eur Heart J 25 2004 1100 1107